https://www.ajmc.com/view/health-care-utilization-study-compares-costs-of-empagliflozin-dpp-4-inhibitors-and-glp-1-agonists-for-t2d
0
0
8/21/22 at 2:34pm
Organization
Ajmc.com
Author
Rose McNulty
51 words
0
Comments
The results suggest that dipeptidyl peptidase-4 (DDP-4) inhibitors, which are widely prescribed in Germany, are not a cost-effective option despite lower drug pricing compared with empagliflozin.
You are the first to view
Create an account
or login to join the discussion